<DOC>
	<DOCNO>NCT00745069</DOCNO>
	<brief_summary>The purpose study examine low high dose tapentadol extend release tablet take orally twice day reduce pain subject suffer chronic moderate severe pain due osteoarthritis knee 4-week period . Subjects steadily increase dose low ( 100 mg ) high ( 200 mg ) dose . Pain relief compare subject take placebo tablet oxycodone extend release tablet , 20 mg . The serum concentration safety tapentadol oxycodone also examine .</brief_summary>
	<brief_title>Efficacy Safety Tapentadol Extended Release Tablets Treatment Moderate Severe Pain Subjects With Knee Osteoarthritis</brief_title>
	<detailed_description>Arthritis common chronic debilitate disease United States ( 43 million people 1 6 ) . Osteoarthritis knee common major cause disability . Pharmacological treatment include follow analgesic : non-steroidal anti-inflammatory drug ( NSAIDs ) , cyclo-oxygenase II ( COX-II ) inhibitor , acetaminophen opioids . Despite numerous available analgesic medication , 60 % 80 % patient suffer chronic pain currently treat inadequately . Opioid analgesic show efficacious chronic non-malignant pain important therapeutic asset . The study 4-week randomized multicenter double-blind , placebo- active-controlled , parallel-group , forced-titration phase 2B study efficacy safety tapentadol extend release ( ER ) 233 mg BID oxycodone PR 20 mg BID vs placebo subject moderate severe chronic pain knee osteoarthritis . Primary efficacy outcome average pain intensity 24 hour last evaluation time 29 day . Safety evaluate report adverse event , laboratory test , vital sign measure , ECGs . This study hypothesis tapentadol extend release effective relieving chronic moderate severe pain knee osteoarthritis compare treatment placebo use 2 dose regimen tapentadol . tapentadol extend release white , fim-coated tablet take orally twice day 4-week period dose steadily increase 100 mg 200 mg ; placebo tablet ; oxycodone extend release tablet , 20 mg .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Subjects clinical diagnosis osteoarthritis knee base symptom and/or radiographic criterion present least 3 month Moderate severe chronic pain due knee osteoarithritis Previously opioid treat subject history withdrawal cessation opioid History seizure disorder , psychiatric disease history head trauma require evaluation hospital base staff , unconsciousness unknown origin . Subjects , investigator 's judgment , wellcontrolled depression anxiety disorder may participate Subjects history uncontrolled hypertension ( systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 95 mmHg ) Intake tricyclic antidepressant , serotonin norepinephrine reuptake inhibitor , barbiturate , neuroleptic , monoamine oxidase inhibitor , antiparkinsonian drug within 30 day prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Tapentadol</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Analgesia</keyword>
	<keyword>Chronic pain</keyword>
</DOC>